Investor Presentaiton
Danaher 2024+: Putting It All Together
ANTICIPATED LONG-TERM CORE REVENUE GROWTH RATE
ANTICIPATED LONG-TERM ANNUAL PERFORMANCE
DANAHER
HSD
HSD
cytiva
PALL
Life Sciences
HSD
LDD
Cepheid.
XXIDT
INTEGRATED DNA FONOLOGIS
aldevron
LS Instruments
DD+
2022 revenue of $8.8B including
leading bioprocessing franchise
>$4.5B 2022 revenue with durable long-
term testing opportunity
Differentiated genomics businesses with
>$1B 2022 revenue
MSD+
Benefit from continued investment spend
& Clinical Dx
CORE REVENUE GROWTH
OPERATING PROFIT
FALL-THROUGH
35-40%
STRONG FREE CASH FLOW
>100% FCF/NI
ACQUISITIONS
FCF+ M&A SPEND
TOP QUARTILE EPS GROWTH
& COMPOUNDING RETURNS
DD+ EPS GROWTH
Now expect HSD long-term core revenue growth
11
DANAHERView entire presentation